This course is part of the Overcoming Clinical Inertia in Primary Care: The When, Why, and How of Basal Insulin Therapy curriculum.
Virtual CME Program
1.00 CME/CE Credit
Overcoming Clinical Inertia in Primary Care: The When, Why, and How of Basal Insulin Therapy for Type 2 Diabetes
Where does basal insulin fit into T2DM management? Expert faculty will discuss guideline recommendations; how to overcome clinical inertia and barriers to insulin use; practical guidance on initiating and titrating insulin in the primary care setting; and the potential role of emerging once-weekly basal insulins.
CME/CE Information
1.00 AMA PRA Category 1 Credits™, 1.00 ABIM MOC or 1.00 AANP, including 1.00 AANP Pharm
Release Date: 10/23/2024
Expiration Date: 10/23/2025
Topics
Learning Objectives
- Explain the detrimental impact of clinical inertia, particularly the effect of failure to initiate basal insulin in a timely manner, on patient outcomes
- Identify and address barriers to insulin uptake among HCPs and people with T2DM
- Implement individualized basal insulin treatment plans according to guideline recommendations
- Discuss data for emerging insulin therapies, such as once-weekly basal insulins, and their potential impact on the management of people with T2DM
Faculty
Javier Morales, MD, FACP, FACE
Associate Clinical Professor of Medicine
The Donald and Barbara Zucker School of Medicine
Hofstra Northwell
Vice President And Principal Trails Investigator
Advanced internal Medicine Group, PC
East Hills, New York
Carol Wysham, MD
Clinical Professor of Medicine
University of Washington School of Medicine
Clinical Endocrinologist
MultiCare/Rockwood Clinic
Spokane, Washington
Disclosures
The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.
Javier Morales, MD, FACP, FACE: Speaker for Abbott, Amgen, Bayer, Boehringer-Ingelheim, Lilly, and Novo Nordisk; Advisor for Abbott, Amgen, Bayer, Boehringer-Ingelheim, Lilly, and Novo Nordisk; Consultant for Abbott, Amgen, Bayer, Boehringer-Ingelheim, Lilly, and Novo Nordisk
Carol H Wysham, MD, FACP: Advisor for Abbott, MannKind; Researcher for AbbVie, Bayer, Eli Lilly, Novo Nordisk; Consultant for Biomea, Novo Nordisk, Speaker for Eli Lilly, MannKind, Novo Nordisk
Pamela Kushner, MD, FAAFP (Moderator): Speaker for Janssen, BI Lilly, AstraZeneca, Bayer, Novo Nordisk, GlaxoSmithKline; Advisor for Novo Nordisk, Lilly, Boehringer-Ingelheim, AstraZeneca, Abbott, Intuity, Pfizer, Janssen; Consultant for Lilly, Boehringer-Ingelheim, AstraZeneca, GlaxoSmithKline, Bayer; Stockholder for Abbott, Speaker for GlaxoSmithKline
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
CME/CE Information
AMA PRA Category 1 Credits™
Accreditation Statement
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement
Pri-Med Institute designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AANP
Accreditation Statement
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of Pri-Med Institute and the Institute for Medical and Nursing Education (IMNE). Pri-Med Institute is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider Number 040308.
Designation Statement
This activity is approved for 1.00 contact hour of continuing education, which includes 1.00 hours of pharmacology.
MOC Credit Information
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Obtaining Credit
Supporters and Partners
Supported by
Novo Nordisk, Inc.
Education Partner
Institute for Medical and Nursing Education, Inc.
Fine Print
The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose personal financial relationships with commercial interests or ineligible companies prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to mitigate real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. All relevant financial relationships have been mitigated Financial disclosures for everyone in control of educational content are provided before the start of each CME/CE activity.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions?
If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.